1,3-Dibromo-2-propanol | CAS:96-21-9

We serve 1,3-Dibromo-2-propanol CAS:96-21-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,3-Dibromo-2-propanol

Chemical Name:  1,3-Dibromo-2-propanol
CAS.NO:96-21-9
Synonyms:  1,3-Dibromo-2-propanol
2-Propanol, 1,3-dibromo-
1,3-dibromopropan-2-ol
 
Molecular Formula:C3H6Br2O
Molecular Weight:217.88700
 
Physical and Chemical Properties:
Density:2.136 g/mL at 25 °C(lit.)
Boiling point:82-83 °C7 mm Hg(lit.)
Melting point:/
Flash point:116 °F
Index of Refraction:1.552
 
Specification:
Appearance:Amber liquid
Purity:≥99.0%
 
Packing:25kg/drum, can also be packaged according to customer requirements
Storage:Storage conditions: Refrigerator
Application:As a solvent, used in organic synthesis.



Contact us for information like 1,3-Dibromo-2-propanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-dibromopropan-2-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-Dibromo-2-propanol Use and application,1,3-Dibromo-2-propanol technical grade,usp/ep/jp grade.


Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?trimethyl benzene-1,3,5-tricarboxylate manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?3,4-Dimethoxyphenylacetonitrile supplier Here’s what Apple told CNN Business in a statement:3,4-Dimethyl-1,2-cyclopentanedione vendor Here’s what Apple told CNN Business in a statement:Here’s what Apple told CNN Business in a statement: